LTFS
ONCY

Ladenburg Thalmann Financial Services’s Oncolytics Biotech ONCY Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$39K Buy
8,390
+7,000
+504% +$7.9K ﹤0.01% 3696
2019
Q3 		$1K Hold
1,390
– – ﹤0.01% 5138
2019
Q2 		$3K Hold
1,390
– – ﹤0.01% 4888
2019
Q1 		$3K Hold
1,390
– – ﹤0.01% 4841
2018
Q4 		$3K Hold
1,390
– – ﹤0.01% 4786
2018
Q3 		$6K Buy
+1,390
New +$6.46K ﹤0.01% 4522

Other funds holding ONCY

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Ladenburg Thalmann Financial Services's ONCY Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services increased its Oncolytics Biotech (ONCY) stake by 504% in Q4 2019, buying an estimated $7.9K and bringing the position to 8,390 shares worth $39K. The position accounts for ﹤0.01% of the portfolio, ranked #3696.

Ladenburg Thalmann Financial Services first reported a position in ONCY in Q3 2018 and has held it in 6 quarters since. 28 funds tracked by Wall St. Rank hold ONCY as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 8,390 shares of Oncolytics Biotech worth $39K as of Q4 2019.
  • Ladenburg Thalmann Financial Services bought 7,000 Oncolytics Biotech shares in Q4 2019, an estimated $7.9K.
  • Oncolytics Biotech made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #3696 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Oncolytics Biotech in Q3 2018 and has held it in 6 quarters since.
  • 28 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.